Pharmacokinetic Considerations in the Treatment of CNS Tumours
- 1 January 2006
- journal article
- review article
- Published by Springer Science and Business Media LLC in Clinical Pharmacokinetics
- Vol. 45 (9), 871-903
- https://doi.org/10.2165/00003088-200645090-00002
Abstract
No abstract availableKeywords
This publication has 177 references indexed in Scilit:
- Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II studyJournal of Neuro-Oncology, 2005
- Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoproteinEuropean Journal Of Cancer, 2004
- Cerebral uptake of mefloquine enantiomers with and without the P‐gp inhibitor elacridar (GF1210918) in miceBritish Journal of Pharmacology, 2004
- Distribution of STI-571 to the Brain Is Limited by P-Glycoprotein-Mediated EffluxJournal of Pharmacology and Experimental Therapeutics, 2002
- Cerebrospinal fluid concentrations of vincristine after bolus intravenous dosingCancer, 2002
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002
- Human Drug Metabolism and the Cytochromes P450: Application and Relevance of In Vitro ModelsThe Journal of Clinical Pharmacology, 2001
- Clinical trials of p-glycoprotein reversal in solid tumoursEuropean Journal Of Cancer, 1996
- Uptake of Adriamycin in tumour and surrounding brain tissue in patients with malignant gliomasActa Neurochirurgica, 1990
- A new aspect of the protective functions of the blood-brain barrier: Activities of four drug-metabolizing enzymes in isolated rat brain microvesselsLife Sciences, 1988